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Abstract:  Chronic Kidney Disease-Mineral Bone Disorder (CKD-MBD) is a systemic disorder 
that affects blood measures of bone and mineral homeostasis, vascular calcification and bone.  
We hypothesized that the accumulation of advanced glycation end-products (AGE) in CKD may 
be responsible for the vascular and bone pathologies via alteration of collagen.  We treated a 
naturally occurring model of CKD-MBD, the Cy/+ rat, with a normal and high dose of the AGE 
crosslink breaker alagebrium (ALT-711), or with calcium in the drinking water to mimic calcium 
phosphate binders for 10 weeks.  These animals were compared to Normal (NL) untreated 
animals.  The results showed that CKD animals, compared to normal animals, had elevated 
BUN, PTH, FGF23 and phosphorus.  Treatment with ALT-711 had no effect on kidney function 
or PTH, but 3 mg/kg lowered FGF23 whereas calcium lowered PTH.   Vascular calcification of 
the aorta assessed biochemically was increased in CKD animals compared to NL, and decreased 
by the normal, but not high dose of ALT-711, with parallel decreases in left ventricular 
hypertrophy.  ALT-711 (3 mg/kg) did not alter aorta AGE content, but reduced aorta expression 
of receptor for advanced glycation end products (RAGE) and NADPH oxidase 2 (NOX2), 
suggesting effects related to decreased oxidative stress at the cellular level.   The elevated total 
bone AGE  was decreased by 3 mg/kg  ALT-711 and both bone AGE and cortical porosity were 
decreased by calcium treatment, but only calcium improved bone properties.  In summary, 
treatment of CKD-MBD with an AGE breaker ALT-711, decreased FGF23, reduced aorta 
calcification, and reduced total bone AGE without improvement of bone mechanics.  These 
results suggest little effect of ALT-711 on collagen, but potential cellular effects.  The data also 
highlights the need to better measure specific types of AGE proteins at the tissue level in order to 




















This article is protected by copyright. All rights reserved.
Key Words:  Bone QCT/µCT, chronic kidney disease-mineral bone disorder (CKD-MBD), 




















This article is protected by copyright. All rights reserved.
Introduction: 
 Chronic Kidney Disease (CKD)- Mineral Bone Disorder (CKD-MBD) is a systemic 
disorder manifested by abnormal mineral metabolism, vascular calcification, and abnormal 
bone(1).  The consequences of CKD-MBD include increased cardiovascular events from left 
ventricular hypertrophy and arterial calcification(2), elevated parathyroid hormone (PTH) and 
fibroblast growth factor-23 (FGF23)(3, 4), and increased risk of fracture(5) due to abnormal 
bone remodeling and increased cortical porosity.  All three end organ manifestations of CKD-
MBD (arteries, heart, and bone) undergo collagen turnover/remodeling as a normal physiologic 
response.  However, pathologic alterations in collagen may affect this remodeling and lead to 
aberrant architecture and abnormal function.   
In diabetes, aging, and CKD, collagen may be altered with advanced glycation end-
products (AGEs).  AGEs represent a heterogeneous group of macromolecules that are formed by 
the non-enzymatic glycation (Amadori rearrangement of a Schiff base) of proteins, lipids, and 
nucleic acids.  AGEs accumulate due to elevated blood glucose, from ingestion of food altered 
with AGEs, and as both downstream and upstream consequences of increased oxidative stress(6). 
The most commonly measured AGEs, pentosidine and N(6)-carboxymethylysine (CML), are 
increased in the circulation and skin and associated with cardiovascular mortality in patients with 
CKD(7, 8).  AGEs are associated with arterial calcification in patients with CKD(9) and induce 
calcification of vascular smooth muscles in vitro(10, 11) and in animal models(12).  In bone, 
studies in older patients with post-menopausal osteoporosis have shown increased AGE 
accumulation and association with bone fragility(13).   In humans(14) and in animals with 
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pathogenic role in multiple components of CKD-MBD and thus a reduction in AGE collagen 
cross links may improve the systemic manifestations of CKD-MBD.   
We therefore tested that hypothesis that ALT-711 (alagebrium), a compound that has 
been shown to effectively lower AGEs in kidney(16), aorta(12), and heart(17) of animals with 
diabetic nephropathy(18), would ameliorate consequences of CKD-MBD.  To test this 
hypothesis, we used our slowly progressive, naturally occurring, Cy/+ rat model that 
spontaneously develops arterial calcification, left ventricular hypertrophy, and compromised 
bone phenotypes (increased cortical porosity and reduced mechanical properties).  
 
Material and Methods: 
Experimental design 
Cy/+ rats are characterized by an autosomal dominant progressive cystic kidney disease.    
The animals have a mutation in Anks6, a gene that codes for the protein SamCystin located at the 
base of cilia.  Although specific function is not fully elucidated, Anks6 binds with Anks3 and 
Bicc1 and thus may alter the nephronopthisis complex(19, 20), but the cilia are not directly 
affected.  In this rat model, CKD-MBD develops spontaneously, with a much faster progression 
to end stage disease in male animals by 30 to 40 weeks of age, whereas female rats do not 
develop azotemia even as old as 21 months(21), or after oophorectomy(22).   The Cy/+IU colony 
of rats has been bred at Indiana University for nearly 20 years.  For the present study, male 
Cy/+IU rats (n=56 hereafter called CKD) and unaffected Sprague Dawley normal littermates (NL; 
n=14) were placed on a casein diet (Purina AIN-76A; 0.7% Pi, 0.6% Ca) at 24 weeks of age in 
order to produce a more consistent CKD-MBD phenotype [38].  Treatment began at 25 weeks of 
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anesthetized with isoflurane and underwent cardiac puncture for blood collection followed by 
exsanguination and bilateral pneumothorax to ensure death.   All animals received an injection of 
calcein (30 mg/kg) fourteen and four days prior to euthanasia.  Heart, aorta, kidney, tibia and 
femora were collected, weighed as appropriate, and stored for analysis.  Left ventricular mass 
index (LVMI) was determined by dividing total heart weight by body weight.   
Multiple studies have tested the effect of ALT-711 in rodent models, using doses of 1 to 
10 mg/kg daily for up to 10 weeks(12, 23-25) and in human studies assessing vascular function, 
doses of 2.8 to 6 mg/kg (assuming 70 kg person) have been used for up to one year(26-28).  We 
therefore chose two doses of ALT-711: 3 mg/kg for efficacy and 15 mg/kg for toxicity.  Five 
groups of animals were compared (n = 14 at start of treatment):  1) Normal littermate animals, 2) 
CKD animals without treatment, 3) CKD animals treated with normal doses of ALT-711 
(3mg/kg i.p. daily) for 10 weeks, 4) CKD animals treated with high doses of ALT-711 (15mg/kg 
i.p. daily) for 10 weeks, and 5) a group of  CKD animals given 3% calcium gluconate in the 
drinking water to simulate a calcium based phosphate binder and lower PTH, inducing a low 
bone turnover phenotype(29).   One of the calcium treated animals, and one of the normal dose 
ALT-711 treated animals died prior to euthanasia.  All procedures were approved by, and carried 
out according to the rules and regulations of, the Indiana University School of Medicine’s 
Institutional Animal Care and Use Committee. 
Blood Biochemistry: 
Blood plasma was analyzed for BUN, creatinine, calcium, and phosphorus using 
colorimetric assays (Point Scientific, Canton, MI, or BioAssay Systems, Hayword, CA). Intact 
PTH and serum C-terminal FGF23 were determined by ELISA kits (Quidel, San Diego, CA).  
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measured using an ELISA kit (Enzo Life Sciences, Farmingdale, NY) and TBARS were 
measured using TBARS assay (TCA method) kit (Cayman Chemical, Ann Arbor, MI).  Serum 
inflammation marker C-reactive protein (CRP) was measured by ELISA (Alpha Diagnostic 
International, San Antonio TX).   Serum AGE levels were determined by OxiSelect Advanced 
End Glycation product Competitive ELISA (Cell BIOLABS, San Diego, CA).  Total serum iron 
levels and total iron binding capacity (TIBC) were determined by the Endocrinology core lab at 
the Indiana University School of Medicine.  
Effect of ALT on in vitro AGE-collage formation:   
In order to confirm that ALT-711 alters collagen AGE formation, Type I collagen was 
solubilized in sterile 0.01 N acetic acid (0.1 µg/µl), poured into culture dishes (100 μg/cm2), and 
dried at room temperature overnight.  The collagen formed was further incubated with or without 
100 mM ribose in the presence or absence of ALT-711 (2 mM) for 3 weeks in a sterile condition.  
AGE-collagen was qualitatively examined by fluorescence (356 nm excitation /440 nm 
emission) by confocal microscope (30).  
Measurement of AGEs in tissue:  
The femoral shaft was flushed with saline to remove marrow followed by incubating with 
Immunocal (Decal Chemical Corporation, Congers, NY) to demineralize the bone for 2-3 days.  
Demineralization end-point determination assays (Polysciences, Warrington, PA) were used to 
verify demineralization of each specimen. The demineralized bone tissues were then hydrolyzed 
in 6 M HCL at 110oC for 16 hours(31).  AGE content was determined using fluorescence 
readings taken with a CLARIOstar high performance microplate reader (BMG LABTECH Inc, 
Cary, NC) at wavelengths of 370nm/440nm excitation/emission against a quinine sulfate 
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each bone specimen was based on the amount of hydroxyproline determined by a hydroxyproline 
assay kit according to manufactures’ instruction (Sigma-Aldrich USA, St. Louis, MO).   AGE 
levels in heart and kidney were similarly measured. 
Bone AGEs were also assessed by HPLC. After mechanical testing, segments of the 
femoral cortex (~3 mm in length) were processed for assessment of enzymatic collagen 
crosslinks and AGEs (pentosidine) by a high performance liquid chromatography (HPLC) 
system (Beckman-Coulter System Gold 168) as previously published(33). Standards of 
pyridinoline (PYD; Quidel), deoxypyridinoline (DPD; Quidel), pentosidine (PE; International 
Maillard Reaction Society) were used. The amount of collagen for each bone specimen was 
based on the amount of hydroxyproline determined by a hydroxyproline assay kit (Sigma-
Aldrich USA, St. Louis, MO) and was used to normalize crosslink concentration (mol/mol 
collagen). 
Aortic arch calcification: 
To quantify aortic calcification, segments of aortic arches were incubated in 0.6 N HCl 
for 48 h and the supernatant analyzed for calcium using the o-cresolphthalein complex 1 method 
(Calcium kit; Pointe Scientific) and normalized by tissue dry weight as previously described 
(34).  
RNA isolation, quantification and real-time PCR: 
 Total RNA from aorta was isolated using miRNeasy Mini Kit (Qiagen).   Target-specific 
PCR primers were obtained from Applied Biosystems.  The gene expression of receptor for AGE 
(RAGE) and NADPH oxidase isoform 2 and 4 (NOX2 and 4) was analyzed by real time PCR 
using Taqman gene expression assay system (TaqMan MGP probes, FAM dye-labeled , Applied 
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amplification plot crosses the threshold was calculated (CT), and the ∆∆CT  method was used to 
analyze the relative changes in mRNA expression and normalized by beta-actin as previously 
described (35).   
Bone assessments 
Micro-Computed Tomography (microCT) was performed using microCT (Skyscan 1172) 
at 12 micron resolution using methods previously published (36). Briefly, a 1 mm region of 
interest starting roughly 0.5 mm from the distal end of the growth plate was used for analysis. 
Trabecular bone volume (BV/TV, %) and cortical porosity were quantified.   Whole femur were 
scanned (Skyscan 1176) at 18 micron resolution to assess geometric properties at the mid-
diaphysis. All CT analyses were done in accordance with standard guidelines (37).   
For dynamic bone histomorphometry, undemineralized proximal tibia were fixed in 
neutral buffered formalin then subjected to serial dehydration and embedded in methyl 
methacrylate (Sigma Aldrich, St. Louis, MO). Serial frontal sections were cut 4 μm-thick and left 
unstained for analysis of fluorochrome calcein labels. Histomorphometric analyses were 
performed using BIOQUANT (BIOQUANT Image Analysis, Nashville, TN). A standard region 
of interest of trabecular bone excluding primary spongiosa and endocortical surfaces was 
utilized. Total bone surface (BS), single-labeled surface (sLS), double-labeled surface (dLS), and 
interlabel distances were measured at 20x magnification. Mineralized surface to bone surface 
(MS/BS; [dLS+sLS/2]/BS*100), mineral apposition rate (MAR; average interlabel distance/10 
days) and bone formation rate (BFR/BS; [MS/BS*MAR]*3.65) were calculated. All 
nomenclature for histomorphometry follows standard usage(38). 
Femoral diaphysis mechanical properties were assessed in 4-point bending on a 
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in saline, and then placed posterior surface down on bottom supports (span = 18 mm). The upper 
supports (span = 6 mm) were brought down in contact with the specimen’s anterior surface, and 
then testing was conducted at a displacement rate of 2 mm/min. Force versus displacement data 
were collected at 10 Hz and structural parameters were determined from curves using a 
customized MATLAB program. Material properties were estimated using standard beam-
bending equations (39).   
Statistics: 
Statistical analyses were conducted by first excluding outliers using ROUT (Q = 1%), 
then checking for normality (p < 0.05 with Anderson-Darling Test).  If normality testing was 
fulfilled, we used  a One-Way ANOVA and, if overall ANOVA  had a p < 0.05, we conducted 
within group comparisons using Dunnett’s post hoc analyses, comparing CKD versus each of the 
other groups (NL, ALT 3mg/kg, ALT 15 mg/kg, and Calcium).   If normality was not fulfilled 
(PTH, FGF23, cortical porosity) then the data for each group was first log transformed, 
normality confirmed, and then the identical analyses as above performed.  The results are 




The effect of ALT-711 on AGE-modified type I collagen matrix in vitro: 
 Type I collagen was incubated with or without 100 mM ribose in the presence or absence 
of ALT-711 for 3 weeks and the resulting collagen was qualitatively examined by confocal 
microscope.  As shown in Figure 1, ribose led to higher amounts of collagen fluorescence 
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However, the addition of ALT-711 at the beginning of glycation (addition of ribose) (Figure 1C) 
or after three weeks of ribose (Figure 1D) resulted in notably lower fluorescence.   
 
The effect of ALT-711 on CKD-MBD biochemical parameters: 
The present study utilized a slowly progressive model of CKD, the Cy/+ rat, in order to 
begin the treatment during mild CKD (approximately stage 3 CKD, glomerular filtration rate 
approximately 50% of normal) with follow up to end stage renal disease.   Elevated AGE 
accumulation measured by skin autofluorescence is observed as early as stage 3 CKD in humans, 
and confers risk of kidney disease progression and cardiovascular disease (40).  There was no 
difference in body weight between the animal groups but, as expected, the cystic kidney weight 
was approximately twice normal in CKD without effect of treatment (Supplemental Table 1).   
The biochemical analyses reflected the presence of CKD-MBD (Table 1):  There was lower 
kidney function at the endpoint as indicated by increased plasma BUN and creatinine levels in 
CKD compared to Normal rats with no effect of treatment.  Calcium levels were higher only in 
calcium drinking water treated CKD animals (to simulate calcium containing phosphate binders) 
relative to CKD.  CKD animals had higher serum phosphorus levels compared to normal animals 
and treatment with calcium in the drinking water normalized these serum phosphorus levels to 
those of non-CKD animals. The serum levels of PTH (Table 1 & supplemental Figure 1A) and 
FGF23 (Table 1 & supplemental Figure 1B) were significantly higher than normal in all CKD 
groups.   As we have previously shown (29), calcium treatment resulted in lower PTH in CKD 
animals. The administration of ALT-711 did not alter biochemical levels or PTH levels, but low 
dose led to significantly lower FGF23 levels compared to other CKD groups (Table 1 & 
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To assess the changes in oxidative stress with ALT-711 treatment, we measured multiple 
markers (Table 2). There was increased oxidative stress as measured by 8-OHdG, a marker of 
DNA oxidation, in CKD rats compared to normal animals.  Calcium, but not ALT-711 at either 
dose, resulted in lower 8-OHdG.  There was no difference in the serum lipid peroxidation marker 
TBARS or inflammation marker CRP between normal and any of the CKD animal groups.  Total 
iron and TIBC were lower in all CKD animal groups compared to normal animals with no effect 
of any dose of ALT or calcium on either variable.    There was no difference among groups in 
serum total AGE levels, although it should be noted that this kit measures predominately N-
(Carboxymethyl)lysine (CML).    
Effect of ALT-711 on the cardiovascular system: 
We have previously demonstrated that calcification occurs exclusively in the medial 
section of the artery(41) and therefore in this study focused on quantifying of the calcification.  
There was higher vascular calcification in untreated CKD compared to normal (p = 0.01; Figure 
2A).  Treatment with ALT-711 at the lower dose (3mg/kg) led to significantly lower aortic arch 
calcification (Figure 2A, p<0.002).  Interestingly, ALT-711 at the higher dose (15mg/kg) had no 
effect on calcification (Figure 2A).   There was no difference for aorta AGE accumulation among 
all groups as assessed by total tissue fluorescence (Figure 2B).   The expression of the receptor 
for AGEs (RAGE) was higher in the untreated CKD animals compared to normal controls, and 
treatment with either lower dose of ALT-711 or calcium reduced expression to levels of that in 
normal animals.  The higher dose of ALT-711 had no effect on RAGE expression (Figure 2C).  
No differences were observed in AGR1 expression in the aorta (data not shown), a more 
constitutively expressed receptor.  In addition, expression of NOX-2 trended higher in untreated 



















This article is protected by copyright. All rights reserved.
treatments(Figure 2D).  No differences were observed in NOX-4 (data not shown) which is 
constitutively expressed.   
In the heart, there was higher LVMI in untreated CKD animals compared to normal and 
only 3 mg/kg ALT-711 reduced LVMI in CKD animals (Table 3).  There was no evidence of 
heart calcification in CKD rats (Table 3).  However, there was increased RAGE expression but 
not NOX2 expression in heart in the CKD rats, unaffected by treatment (Table 3).   
Effect of ALT-711 on bone: 
There were higher levels of AGEs assessed by total fluorescence in femoral bone tissue 
from untreated CKD rats compared to normal animals (Figure 3); treatment with 3 mg/kg ALT-
711 and calcium normalized levels while the higher dose of ALT-711 had no effect (Figure 3).  
HPLC (supplemental Figure 2) demonstrated decreased pyridinoline/collagen in CKD compared 
to normal rats, which increased with both 3 mg/kg and calcium treatment.   However, there was 
no change in the AGE pentosidine.   MicroCT assessment of proximal tibial bone demonstrated 
that there was lower trabecular bone volume fraction in CKD rats compared to normal animals 
(Figure 4A).  As we have previously observed (29, 36) calcium treated CKD rats had higher 
trabecular bone volume fraction; however there was no effect of either ALT-711 dose on 
trabecular BV/TV (Figure 4A). CKD rats also had higher cortical porosity compared to normal 
rats and CKD rats treated with calcium (Figure 4B. Dynamic histomorphometry demonstrated 
increased trabecular bone formation rate in CKD rats compared to normal animals (Figure 4C). 
As shown in previous studies, calcium treatment reduced trabecular remodeling (29).  Neither 
dose of ALT-711 had any effect on cortical porosity or bone formation rates.  Bone mechanical 
analysis demonstrated that while several properties were lower in untreated CKD animals, 
calcium, but not either dose of ALT-711 treatment, normalized these mechanical properties in 
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Discussion: 
 In the present study we tested the hypothesis that a reduction in AGE formation of 
collagen, using ALT-711, would have favorable effects on the manifestations of CKD-MBD.   In 
the CKD animals 3 mg/kg reduced arterial calcification, aorta RAGE expression, and NOX2 
expression.  Calcium treatment only reduced RAGE and NOX2 expression. There was no effect 
of  ALT-711 on calcification of the heart, but there was a reduction in left ventricular mass index 
with the 3 mg/kg dose, presumably due to reduction in arterial calcification thereby reducing 
afterload and/or from the decreased in serum FGF23, a known inducer of LVH(4).  In bone, 
there was a decrease in cortical porosity and bone formation rate with calcium as we have 
previously reported(29), however, ALT-711 had no effect.     There was an increase in total 
fluorescence (a marker of total AGEs) but not the AGE pentosidine in CKD, with a decrease in 
bone AGE in response to normal dose ALT-711.  These changes did not result in improved bone 
mechanical properties.  The administration of either dose of ALT-711 did not affect markers of 
inflammation or oxidative stress which would have been expected as a result of decreased AGE 
levels.  Taken together, the efficacy of ALT-711 appeared to predominately affect vasculature, 
consistent with human studies demonstrating reduced pulse wave velocity(27, 28). 
 We have previously shown that vascular calcification is accelerated in vitro by glucose, 
high phosphorus, and uremic serum (42, 43), via the de-differentiation of VSMC to an 
osteochondrocytic- like cell with upregulation of the osteoblast transcription factor RUNX2 is a 
key step.  Tanikawa (44) found similar phenotypic changes and increased calcification of human 
VSMC cultured with glycated albumin vs. non-glycated albumin, and in serum from diabetic 
patients versus normal controls; the calcification was inhibited through anti-RAGE antibodies.  
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calcification inhibitor matrix gla protein), 10 mg/kg ALT-711 given in the food, reduced 
femoral, but not aortic, calcification and total AGE content(12).  In vitro studies demonstrated 
that AGEs needed to bind to RAGE in order to inhibit calcification.  Activation of RAGE 
induces multiple cell signaling pathways  that have been shown to be involved in arterial 
calcification in vitro including JAK/Stat, NFKβ, MAPK and ERK signaling(6).  In addition, 
activation of RAGE increases oxidative stress, mediated in part by NOX(45).  In the current 
study we found that 3 mg/kg of ALT-711 decreased expression of RAGE and decreased NOX 
expression in the aorta.     
Activation of RAGE signaling is known to increase oxidative stress and systemic 
oxidative stress activates cellular RAGE expression(11, 46).  We observed increased oxidative 
stress in our CKD animals compared to normal littermates, but no effect of ALT-711 to reduce 
oxidative stress.   In the adenine-induced CKD and 5/6th nephrectomy and obese rat models, 
arterial calcification was prevented by the anti-oxidants tempol(47) and Vitamin E(48) similar to 
our findings of decreased calcification at 3 mg/kg of ALT-711.  In contrast, we failed to see any 
effect on vascular calcification with N-acetylcystine in the Cy/+ model (unpublished data) or 
high dose ALT-711.  The discrepant data could be due to differences in the acute versus chronic 
nature of CKD and/or the high phosphate diets used in the adenine and 5/6th nephrectomy animal 
models, or that high dose ALT-711 and N-acetylcystine are ineffective in reducing oxidative 
stress or RAGE expression in CKD.     Thus, in the present study, the data suggests that the 
effects of 3 mg/kg ALT-711 are mediated by RAGE and subsequent intracellular ROS rather 
than decreased systemic oxidative stress.  
Similar to the efficacy of 3 mg/kg ALT-711 in reducing arterial calcification, we did see 
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ALT-711.  We have previously observed increased pentosidine, one specific AGE found in bone, 
at an early stage of disease (30 weeks), in our CKD (Cy/+) animal model together with impaired 
bone mechanics (49), and Mitome also found increased pentosidine in bone from dialysis 
patients compared to controls and impaired mineralization(14).  In the current study, we found 
increased total bone fluorescence (AGEs), but no change in pentosidine in bone at 35 weeks, 
with no improvement in bone mechanics with either dose of ALT-711.  Although we can’t 
explain the discrepancy between this outcome and our past work, it is worth noting that 
pentosidine represents just one of several AGEs in the bone and thus changes in AGEs could be 
driven through differential processes that are not completely understood.  In addition, Thomas et 
al recently demonstrated that the bone content of non-fluorescent AGEs, such as CML, may be 
40-100 times more common than pentosidine (50). These data highlight the complexity of AGE 
accumulation in bone and unfortunately leave more questions than answers with respect to AGE 
changes in CKD. 
The present study showed increased cortical porosity and low trabecular bone volume in 
the CKD animals; these were both reversed with calcium-induced lowering of PTH as in our 
previous studies but not ALT-711.  Although there was no change in PTH with ALT-711, the 
FGF23 levels were reduced by 45 to 52% with 3 mg/kg ALT-711 doses.   This may have been 
secondary to a direct effect of RAGE on osteoblasts/osteocytes to reduce FGF23(51), or indirect 
effects of local inflammation to reduce FGF23 production from osteoblasts(52).   The latter 
seems most likely given no effect on bone remodeling.  Another possibility is that changes in the 
AGE content of collagen in response to ALT-711 were enough to affect osteocyte cell function 
but not significant enough to affect biomechanics.  More studies would be needed to understand 
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Interestingly, the higher dose of ALT-711 was ineffective compared to the 3 mg/kg dose 
for all measures for reasons that are not clear.  ALT-711 is thought to be an AGE breaker, 
chemically cleaving the carbon-carbon bond in α-dicarbonyl containing cross-linked structures 
and our in vitro studies (Figure 1) suggest that ALT-711 can function as both an inhibitor of 
AGE formation and a breaker of already formed AGEs.  However, this mechanism of breaking is  
controversial(53) and some authors believe the primary effect of ALT-711 is by  chelating 
activities of metal-catalyzed oxidation(54).  In order to further understand the lack of a dose 
response, we performed a series of studies.  First, it is worth noting that in the aorta, only the 3 
mg/kg dose reduced calcification and RAGE/NOX expression, raising the possibility that RAGE 
is differentially expressed at the two doses and this signaling difference explains the lack of dose 
efficacy.  Second, we confirmed there was no solubility issue with the 3 versus 15 mg/kg dose.  
Third, there was no increased mortality, or local injection site irritation to suggest altered dose 
delivery.  Fourth, we measured iron levels to test the hypothesis that there may be differences in 
the metal-catalyzed oxidation and did not find any differences.  Unfortunately, we did not collect 
the samples in a way to measure copper levels.  Finally, we conducted dynamic bone 
histomorphometry to determine if the doses differentially affected trabecular bone remodeling, 
yet there was no significant effect. Thus, at this time we cannot explain the lack of dose effect at 
15 mg/kg, but hypothesize that there may be differences in cell signaling induced by the two 
doses studied.  Further work is needed to fully understand the lack of dose-dependent effects.   
 In summary, 3 mg/kg ALT-711 reduced aorta expression of RAGE, NOX2, and arterial 
calcification, decreased serum FGF23 levels, and reduced total bone AGE.  The high dose (15 
mg/kg) of ALT-711 had no effect on measured parameters.  There was no improvement in the 
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These results highlight the need to better measure specific types of AGE proteins at the tissue 
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Figure legends: 
Figure 1: The effect of ALT-711 on AGE formation on collagen matrix in vitro.  
Type I collagen was incubated with or without ribose (100 mM) in the presence or 
absence of ALT-711 (2 mM) for 3 weeks, or ALT-711 was added after ribose-collagen 
incubation for 3 weeks and then incubated for additional 7 days. AGE-collagen was examined 
qualitatively by fluorescence (356 nm excitation /440 nm emission) by confocal microscopy.  
The results demonstrated an apparent increase in AGE formation with ribose (B) compared to 
control (A).  Addition of ALT-711 at the beginning of glycation (C) or after three weeks of 
ribose (D) prevented and reduced, respectively, AGE formation.   
 
Figure 2: The effect of ALT-711 on aortic expression of RAGE and NOX and vascular 
calcification in CKD rats:  
 There was increased vascular calcification in CKD animals (A) and treatment with ALT-711 at 
normal dose (3mg/kg) but not the higher dose (15mg/kg) significantly decreased calcification in 
CKD rats (A). There was no difference in total AGE accumulation in all animal groups (B).  
Expression of the RAGE in aorta was increased in CKD animal compared to normal rats (C) and 
treatment with 3 mg/kg ALT-711 or calcium significantly reduced the expression of RAGE in 
CKD rats (C).  In addition, aortic NOX2 expression was increased in CKD animals compared to 
normal rats (D) and treatment with 3 mg/kg ALT-711 or calcium significantly reduced the 
expression of NOX2 in CKD rats (D).  Data are shown as mean ± SD (n =10-13 rats each group). 
One-Way ANOVA, and if p < 0.05, Dunnett’s multiple comparison test for group vs CKD with p 
value shown in graph.  
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The demineralized femur bone tissues were then hydrolyzed in 6 M HCL and total AGE 
content was determined using fluorescence microplate reader and normalized by the collagen 
content for the sample. There was increased accumulation of AGE in femoral shaft from CKD 
rats compared to normal rats. Treatment with ALT-711 at normal dose (3mg/kg) or calcium 
reduced bone AGE accumulation in CKD rats.  However, ALT-711 at high dose (15mg/kg) had 
no effect.  Data are shown as mean ± SD (n =10-13 rats each group). One-Way ANOVA, and if 
p < 0.05, Dunnett’s multiple comparison test for group vs CKD with p value shown in graph. 
 
Figure 4: The effect of ALT-711 on bone architecture in CKD rats:  
The bone architecture was analyzed by MicroCT.  The results demonstrated that (A) 
trabecular bone volume (BV/TV) was lower in CKD rats compared to either Normal rats or CKD 
rats treated with calcium.  Cortical porosity (B) and Bone Formation rate (BFR/BS; C) were 
higher in CKD rats compared to Normal rats or CKD rats treated with calcium.  Data are shown 
as mean ± SD (n =10-13 rats each group). One-Way ANOVA, and if p < 0.05, Dunnett’s 
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Table 1: Serum Biochemistries: 






PTH (pg/ml) FGF23 (pg/ml) 
Normal 18.20±3.84* 0.74±0.22* 8.02±1.07 3.47±0.40* 145±44* 412±191* 






49.50±4.66 1.46±0.48 7.52±1.68 8.02±2.41 1285±738 2499±516# 
CKD/ALT-711 
(15 mg/kg) 
49.45±6.86 1.32±0.20 8.73±1.52 6.93±1.75 1137±765 3189±598 
CKD/3% Ca 46.20±7.59 1.18±0.22* 9.92±1.73# 5.46±1.40* 57±32* 11008±2955 
PTH: parathyroid hormone; FGF23: fibroblast growth factor 23. Data are shown as mean ± SD (n =10-13 rats each group). All of the 
measures were significantly different by ANOVA.  Within group comparisons vs. CKD by Dunnett’s test:   *p < 0.001, vs. CKD, # p < 






















This article is protected by copyright. All rights reserved.
Tables 
Table 2: Serum oxidative stress/inflammation markers  










13.28±1.97* 39.09±3.97 595.1±37.73 55.8±10.06# 645.5±21.12* 
CKD 77.80±9.60 21.8±4.29 42.26±2.29 589.8±57.07 43.46±4.91 530.3±40.72 
CKD/ALT-711 
(3 mg/kg) 
73.15±8.74 20.12±6.40 34.18±3.16 582.3±59.08 41.18±3.10 543.5±14.34 
CKD/ALT-711 
(15 mg/kg) 
82.52±9.32 23.98±4.01 37.04±0.99 590.9±89.99 39.00±12.28 544.5±25.7 
CKD/3% Ca 76.82±8.92 15.29±4.23# 39.6±5.52 588.9±80.65 48.98±7.46 546.5±27.96 
AGE: Advanced glycation end products; 8-OHdG: 8-hydroxyguanosine; TBARS: Thiobarbituric Acid Reactive Substances; CRP: C-
reactive protein; TIBC: total iron binding capacity.  Data are shown as mean ± SD (n =10-13 rats each group). 8-OHDG, Iron, and 
TIBC were significantly different by ANOVA.  Within group comparisons vs. CKD by Dunnett’s test:  *p < 0.01 vs. CKD, # p < 0.05 
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Table 3: Cardiovascular parameters 
 
LVMI: Left ventricular mass index.  Data are shown as mean ± SD (n =10-13 rats each group).  
Only LVMI was significantly different by ANOVA.  Within group comparisons vs. CKD by Dunnett’s test:  *p < 0.01 vs. CKD #p < 
0.01 vs. CKD.  5, NL vs. CKD; #p<0.05, CKD vs. CKD with treatment. 









0.79±0.10 0.89±0.26# 1.04±0.18 
CKD 3.45±0.38 0.76±0.17 1.46±0.58 0.98±0.23 
CKD/ALT-711 
(3 mg/kg) 
3.10±0.33# 0.78±0.21 1.38±0.43 1.09±0.28 
CKD/ALT-711 
(15 mg/kg) 
3.21±0.27 0.80±0.20 1.37±0.37 1.13±0.66 
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699 ± 58 495 ± 
44* 
97 ± 13 153 ± 7* 4.78 ± 0.41 4.46 ± 
0.59 





1.31 167 ± 34 
704 ± 





















1.41 166 ± 27 
755 ± 
184 434 ± 36 82 ± 25 124 ± 18 4.80 ± 0.55 
4.18 ± 
1.27 







15* 654 ± 57 
499 ± 
44* 86 ± 12 163 ± 11* 5.52 ±0.63* 
4.09 ± 
0.59 
CSMIp =polar cross sectional moment of inertia.  Data are shown as mean ± SD (n =10-13 rats each group).  Ultimate force, stiffness, 
ultimate stress, and modulus were significantly different by ANOVA.  Within group comparisons vs. CKD by Dunnett’s test:  *p < 
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